Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FBIO
HoldUnloved QualityFortress Biotech, Inc. · Healthcare · United States · $92M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Fortress Biotech, Inc. is a biopharmaceutical company that utilizes a unique business model focused on acquiring, developing, and commercializing clinical-stage drug candidates. The company's competitive moat lies in its specialized business development engine, which identifies and acquires undervalued pharmaceutical assets to be developed through its network of subsidiary companies. It operates as a diversified biotech incubator, generating revenue from commercialized products while maintaining significant upside from its extensive clinical pipeline.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 75.7M | 84.5M | 57.7M | 63.3M | -5.8% | 68.5M | 78.8M | 113.2M | 33.8% |
| EPS | -3.23 | -3.85 | -2.69 | -0.07 | — | 2.77 | 2.55 | -1.00 | — |
| Shares | 33.2M | 33.2M | 27.9M | 31.4M | -5.6% | 33.4M | — | — | — |
| Debt | 127.3M | 84.7M | 76.0M | 74.3M | -16.4% | 53.3M | — | — | — |
| Equity | 41.7M | 22.5M | 22.7M | 49.9M | 6.1% | — | — | — | — |
| Op CF | -179.4M | -128.2M | -80.2M | -65.8M | — | 125.9M | — | — | — |
| Inv CF | -22.9M | -2.1M | -15.0M | 10.1M | — | — | — | — | — |
| Fin CF | 75.3M | 32.7M | 70.6M | 77.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FBIO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FBIO | Fortress Biotech, Inc.(you) | $92M | 45 | Hold |
| RLYB | Rallybio Corporation | $89M | 54 | Hold |
| BSEM | BioStem Technologies, Inc. | $63M | 39 | Hold |
| XLO | Xilio Therapeutics, Inc. | $59M | 38 | Hold |
| BOLD | Boundless Bio, Inc. | $64M | 36 | Hold |
| ACRV | Acrivon Therapeutics, Inc. | $88M | 29 | Sell |
| PTHS | Pelthos Therapeutics Inc. | $95M | 26 | Sell |
| SEER | Seer, Inc. | $110M | 28 | Sell |
| APLM | Apollomics, Inc. | $77M | 28 | Sell |
| CSBR | Champions Oncology, Inc. | $68M | 30 | Sell |
Peer medians: ROE -30.7% · P/E 27.1x · Gross margin 58.1%